A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT ID: NCT06101134
Last Updated: 2025-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
100 participants
INTERVENTIONAL
2023-11-06
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
NCT05297565
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
NCT02714218
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
NCT07091695
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT05704647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Metastatic Melanoma
relatlimab+nivolumab
Specified dose on specified days
relatlimab+nivolumab+rHuPH20
Specified dose on specified days
Cohort 2: Resected Melanoma
nivolumab
Specified dose on specified days
nivolumab+rHuPH20
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
relatlimab+nivolumab
Specified dose on specified days
relatlimab+nivolumab+rHuPH20
Specified dose on specified days
nivolumab
Specified dose on specified days
nivolumab+rHuPH20
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have a low level of disability and cancer that is considered advanced for metastatic melanoma and at risk for becoming advanced (intermediate) or advanced for resected melanoma
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0007
Anchorage, Alaska, United States
Local Institution - 0013
Phoenix, Arizona, United States
Local Institution - 0010
San Francisco, California, United States
Local Institution - 0034
Atlanta, Georgia, United States
Local Institution - 0032
Edgewood, Kentucky, United States
Local Institution - 0028
Albuquerque, New Mexico, United States
Local Institution - 0037
Edmonds, Washington, United States
Local Institution - 0036
Issaquah, Washington, United States
Local Institution - 0030
Seattle, Washington, United States
Local Institution - 0015
Las Condes, Santiago Metropolitan, Chile
Local Institution - 0005
Concepción, , Chile
Local Institution - 0019
Thessaloniki, B, Greece
Local Institution - 0014
Athens, I, Greece
Local Institution - 0029
Marousi, I, Greece
Local Institution - 0023
Holargos, Athens, , Greece
Local Institution - 0008
Piraeus, , Greece
Local Institution - 0033
Thessaloniki, , Greece
Local Institution - 0017
Bergamo, BG, Italy
Local Institution - 0035
Meldola, FC, Italy
Local Institution - 0018
Milan, MI, Italy
Local Institution - 0012
Padua, PD, Italy
Local Institution - 0021
Roma, RM, Italy
Local Institution - 0004
Torino, TO, Italy
Local Institution - 0026
Napoli, , Italy
Local Institution - 0011
Barcelona, B, Spain
Local Institution - 0022
Barcelona, B, Spain
Local Institution - 0009
Cartagena, MU, Spain
Local Institution - 0020
Badalona, , Spain
Local Institution - 0027
Cantabria, , Spain
Local Institution - 0003
San Pedro Alcántara, Málaga, , Spain
Local Institution - 0006
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1289-5947
Identifier Type: OTHER
Identifier Source: secondary_id
2023-504515-33-00
Identifier Type: OTHER
Identifier Source: secondary_id
CA224-1044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.